Hao Zhang, Wenjing Yan, Jinhui Wang, Shuqian Xie, W Andy Tao, Chien-Wei Lee, Xing Zhang, Guiyuan Zhang, Yufeng Liu, Dong Wei, Jing Hu, Haohan Liu, Fengying Liu, Yamei Nie, Xue Chen, Hongtao Xu, Jiang Xia, Shizhi Wang
Osteoarthritis (OA) is the most prevalent degenerative cartilage disease, but no effective treatment is currently available to ameliorate the dysregulation of cartilage catabolism. Cartilage degeneration is closely related to the change in the physiology of chondrocytes: for example, chondrocytes of the OA patients overexpress matrix metallopeptidase 13 (MMP13), a.k.a. collagenase 3, which damages the extracellular matrix (ECM) of the cartilage and deteriorate the disease progression. Inhibiting MMP13 has shown to be beneficial for OA treatments, but delivering therapeutics to the chondrocytes embedded in the dense cartilage is a challenge...
April 4, 2024: Journal of Controlled Release